Scarica l'app Stockscreener
16.75
3.72%
0.60
Precedente Chiudi:
$16.15
Aprire:
$16.32
Volume 24 ore:
48,081
Relative Volume:
0.66
Capitalizzazione di mercato:
$775.20M
Reddito:
-
Utile/perdita netta:
$-75.28M
Rapporto P/E:
-8.393
EPS:
-1.9957
Flusso di cassa netto:
$-57.45M
1 W Prestazione:
+8.06%
1M Prestazione:
-8.97%
6M Prestazione:
+12.49%
1 anno Prestazione:
+39.70%
Intervallo 1D:
$16.19
$16.89
Intervallo di 1 settimana:
$14.00
$16.89
Portata 52W:
$10.79
$23.08
Oculis Holding Ag Stock (OCS) Company Profile
Nome
Oculis Holding Ag
Settore
Industria
Telefono
-
Indirizzo
-
Confronta OCS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
OCS
Oculis Holding Ag
|
16.75 | 775.20M | 0 | -75.28M | -57.45M | -1.9957 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.22 | 122.24B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
554.18 | 59.73B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
580.94 | 35.43B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
237.77 | 30.77B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
96.52 | 23.20B | 3.30B | -501.07M | 1.03B | -2.1146 |
Oculis Holding Ag Stock (OCS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-05 | Iniziato | Chardan Capital Markets | Buy |
| 2023-10-05 | Iniziato | Stifel | Buy |
| 2023-06-14 | Iniziato | BofA Securities | Buy |
| 2023-06-12 | Iniziato | H.C. Wainwright | Buy |
| 2023-06-08 | Iniziato | Robert W. Baird | Outperform |
| 2023-05-10 | Iniziato | Pareto | Buy |
| 2023-04-28 | Iniziato | Wedbush | Outperform |
Mostra tutto
Oculis Holding Ag Borsa (OCS) Ultime notizie
Oculis completes enrolment in trials for diabetic macular oedema eye drops - Yahoo Finance
Oculis completes enrollment for pivotal DME treatment trials By Investing.com - Investing.com South Africa
Oculis completes enrollment for pivotal DME treatment trials - Investing.com
Oculis Wraps Up Patient Enrollment in Late-stage Studies of Topical Eye Drug - MarketScreener
Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema - The Manila Times
Oculis lýkur innritun sjúklinga í báðar DIAMOND fasa 3 rannsóknirnar á OCS-01 sem meðferð við sjónhimnubjúg af völdum sykursýki - GlobeNewswire Inc.
(OCS) Trading Signals - news.stocktradersdaily.com
A First Look At Oculis Holding AG: Revenues Still Several Years Away (NASDAQ:OCS) - Seeking Alpha
REG-Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond - TradingView
Oculis Holding AG (NASDAQ:OCS) Short Interest Update - Defense World
Oculis Holding AG (NASDAQ:OCS) Short Interest Down 14.1% in February - Defense World
Oculis' Insider Moves: A Glimpse into the Company's Future? - AInvest
Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities - MarketScreener
Insider Buying: Oculis Holding Independent Director Bought CHF326k Of Shares - simplywall.st
Lionel Carnot Spends CHF326k On Oculis Holding Stock - Yahoo Canada Finance
Equities Analysts Set Expectations for Oculis Q1 Earnings - The AM Reporter
HC Wainwright Comments on Oculis’ Q1 Earnings (NASDAQ:OCS) - Defense World
Robert W. Baird Boosts Oculis (NASDAQ:OCS) Price Target to $41.00 - Defense World
Chardan Capital Reaffirms Buy Rating for Oculis (NASDAQ:OCS) - Defense World
HC Wainwright Lowers Oculis (NASDAQ:OCS) Price Target to $29.00 - Defense World
Oculis (NASDAQ:OCS) Sees Strong Trading Volume After Analyst Upgrade - Defense World
Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update - Informazione.it
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - Marketscreener.com
(OCS) Investment Analysis - Stock Traders Daily
Oculis Holding AG (OCS) Reports Q4 Loss, Misses Revenue Estimates - MSN
Stifel maintains Buy on Oculis shares, price target at $35 By Investing.com - Investing.com Australia
H.C. Wainwright cuts Oculis stock target to $29, keeps Buy rating - Investing.com Australia
H.C. Wainwright cuts Oculis stock target to $29, keeps Buy rating By Investing.com - Investing.com South Africa
Oculis Holding AG Faces Heightened Cybersecurity Risks Amid Geopolitical Tensions - TipRanks
Oculis price target raised to $32 from $31 at BofA - TipRanks
Oculis (NASDAQ:OCS) Shares Gap Down Following Weak Earnings - Defense World
Oculis Holding AG Reports 2024 Financial Results - TipRanks
Oculis Reports 2024 Fourth Quarter Net Loss, Completes $100 Million Equity Financing to Support Pipeline - Vision Monday
Stifel maintains Buy on Oculis shares, price target at $35 - Investing.com
Oculis Holding AG reports results for the quarter ended December 31Earnings Summary - TradingView
Oculis Holding AG Reports 2024 Financial Results and Clinical Progress - TipRanks
Oculis (OCS) Projected to Post Quarterly Earnings on Monday - Defense World
(OCSAW) On The My Stocks Page - news.stocktradersdaily.com
Oculis to Present at Upcoming March Investor Conference - The Manila Times
(OCS) Investment Report - Stock Traders Daily
(OCS) On The My Stocks Page - Stock Traders Daily
Oculis Holding AG (NASDAQ:OCS) Short Interest Down 68.6% in January - MarketBeat
Oculis (NASDAQ:OCS) Shares Down 7.2%Should You Sell? - MarketBeat
Oculis Holding AG Prices $100 Million Oversubscribed Share Offering - TipRanks
Oculis Holding Prices Offering of 5 Million Shares -February 14, 2025 at 04:36 am EST - Marketscreener.com
Biopharmaceutical Company Oculis Seeks $100 Million from Share Sale -February 14, 2025 at 12:56 am EST - Marketscreener.com
Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares - The Manila Times
Major Funding Breakthrough: Oculis Secures $100M for Revolutionary Eye Treatment Development - StockTitan
Oculis Raises Massive $100M War Chest: Major Pipeline Expansion for Revolutionary Eye Treatment - StockTitan
Oculis Holding Ag Azioni (OCS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):